DengiAll: India's Hope in the Fight Against Dengue
DengiAll, an indigenous one-shot dengue vaccine, is undergoing a Phase III clinical trial in India with 70% of participants enrolled. Overseen by the Indian Council of Medical Research, the trial aims to evaluate the vaccine's efficacy against all four dengue virus serotypes. The trial spans 20 sites nationwide.
- Country:
- India
India's indigenous dengue vaccine, DengiAll, progresses through its Phase III clinical trial, with Minister Prataprao Jadhav announcing 70% participant enrolment completion during a Lok Sabha session.
The Indian Council of Medical Research spearheads this multicentre, randomized, double-blind study, evaluating DengiAll's effectiveness across 20 sites in India. The trial aims to tackle all four dengue virus serotypes, enhancing protective measures.
In 2024, over 5 lakh dengue cases were confirmed in India, highlighting the urgent need for a vaccine. With no current licensed vaccines, DengiAll's success could be pivotal in India's dengue control strategy.
(With inputs from agencies.)
- READ MORE ON:
- Dengue
- Vaccine
- India
- DengiAll
- ICMR
- Clinical Trial
- Health
- Prataprao Jadhav
- Serotypes
- NCDC
Advertisement
ALSO READ
Chhattisgarh’s Health Scheme Reaches Millions, Yet Struggles With Cost Efficiency
Toxic Heat: WHO Report Links Rising Temperatures and Pollution to Health Crises
New Horizons in Health: Innovations and Challenges
AI Revolutionizing Indian Healthcare: Key Insights from Future Health Index 2025
PIL Sparks Hope for Better Compliance with Mental Healthcare Act
Google News